Author:
Fadini Gian Paolo,Bonora Benedetta Maria,Avogaro Angelo
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference10 articles.
1. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
2. Cherney DZ, Perkins BA (2014) Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes 38:356–363
3. U.S. Food and Drug Administration (2015) Drug safety communications. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from:
www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf
. Accessed 6 Apr 2017
4. European Medicines Agency (2015) Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined. Available from:
www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf
. Accessed 6 Apr 2017
5. Ferrannini E, Baldi S, Frascerra S et al (2016) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190–1195
Cited by
200 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献